The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors
Abstract
Infection can protect against subsequent disease by induction of both humoral and cellular immunity, but inert protein-based vaccines are not as effective. In this study, we present a new vaccine design, with Ag covalently conjugated to solid core nano-beads of narrowly defined size (0.04–0.05 μm) that localize to dendritic cells (DEC205+ CD40+, CD86+) in draining lymph nodes, inducing high levels of IFN-γ production (CD8 T cells: precursor frequencies 1/5000 to 1/1000) and high Ab titers in mice. Conjugation of Ag to these nano-beads induced responses that were significantly higher (2- to 10-fold) than those elicited by other bead sizes, and higher than a range of currently used adjuvants (alum, QuilA, monophosphoryl lipid A). Responses were comparable to CFA/IFA immunization for Abs and ex vivo peptide-pulsed dendritic cell immunization for CD8 T cells. A single dose of Ag-conjugated beads protected mice from tumors in two different model challenges and caused rapid clearance of established tumors in mice. Thus, a range of Ags conjugated to nano-beads was effective as immunogens in both therapeutic and prophylactic scenarios.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Mouse and human dendritic cell subtypes
Shortman, K., & Liu, Y.-J. (2002) · Nature Reviews Immunology · doi:10.1038/nri746 · Cited by 2,291
Antigen Presentation and T Cell Stimulation by Dendritic Cells
Guermonprez, P., Valladeau, J., Zitvogel, L., Théry, C., & Amigorena, S. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064828 · Cited by 1,926
Natural adjuvants: Endogenous activators of dendritic cells
Gallucci, S., Lolkema, M., & Matzinger, P. (1999) · Nature Medicine · doi:10.1038/15200 · Cited by 1,602
Introduction of soluble protein into the class I pathway of antigen processing and presentation
Moore, M. W., Carbone, F. R., & Bevan, M. J. (1988) · Cell · doi:10.1016/s0092-8674(88)91043-4 · Cited by 1,092
CD8+ T Cell Effector Mechanisms in Resistance to Infection
Harty, J. T., Tvinnereim, A. R., & White, D. W. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.275 · Cited by 726
Phagosomes are competent organelles for antigen cross-presentation
Houde, M., Bertholet, S., Gagnon, E., Brunet, S., Goyette, G., Laplante, A., Princiotta, M. F., Thibault, P., Sacks, D., & Desjardins, M. (2003) · Nature · doi:10.1038/nature01912 · Cited by 699
Recent developments in adjuvants for vaccines against infectious diseases
O'Hagan, D. T., MacKichan, M. L., & Singh, M. (2001) · Biomolecular Engineering · doi:10.1016/s1389-0344(01)00101-0 · Cited by 332
Ada, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmra011223 · Cited by 291
Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity
Falo, L. D., Kovacsovics-Bankowski, M., Thompson, K., & Rock, K. L. (1995) · Nature Medicine · doi:10.1038/nm0795-649 · Cited by 289
Cited by
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Bachmann, M. F., & Jennings, G. T. (2010) · Nature Reviews Immunology · doi:10.1038/nri2868 · Cited by 2,106
Immunological properties of engineered nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.223 · Cited by 1,823
Sharifi, S., Behzadi, S., Laurent, S., Laird Forrest, M., Stroeve, P., & Mahmoudi, M. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15188f · Cited by 1,460
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O'Neil, C. P., Lee, L. K., Swartz, M. A., & Hubbell, J. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1332 · Cited by 1,350
Nanotechnology: Intelligent Design to Treat Complex Disease
Couvreur, P., & Vauthier, C. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0284-8 · Cited by 948
Zhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C., & Middelberg, A. P. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.069 · Cited by 919
Minireview: Nanoparticles and the Immune System
Zolnik, B. S., González-Fernández, A., Sadrieh, N., & Dobrovolskaia, M. A. (2010) · Endocrinology · doi:10.1210/en.2009-1082 · Cited by 914
Applications of nanotechnology for immunology
Smith, D. M., Simon, J. K., & Baker Jr, J. R. (2013) · Nature Reviews Immunology · doi:10.1038/nri3488 · Cited by 767
Synthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
Nanotoxicity: the growing need for in vivo study
Fischer, H. C., & Chan, W. C. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.11.008 · Cited by 717
The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment
Yang, M., Li, J., Gu, P., & Fan, X. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.12.010 · Cited by 670
Self-citationNiikura, K., Matsunaga, T., Suzuki, T., Kobayashi, S., Yamaguchi, H., Orba, Y., Kawaguchi, A., Hasegawa, H., Kajino, K., Ninomiya, T., et al. (2013) · ACS Nano · doi:10.1021/nn3057005 · Cited by 638
The perfect mix: recent progress in adjuvant research
Guy, B. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1681 · Cited by 620
Pathogen recognition and development of particulate vaccines: Does size matter?
Xiang, S. D., Scholzen, A., Minigo, G., David, C., Apostolopoulos, V., Mottram, P. L., & Plebanski, M. (2006) · Methods · doi:10.1016/j.ymeth.2006.05.016 · Cited by 602
Self-citationEngineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 594
Virus-like particles: Passport to immune recognition
Grgacic, E. V. L., & Anderson, D. A. (2006) · Methods · doi:10.1016/j.ymeth.2006.07.018 · Cited by 582
Nanotoxicity: An Interplay of Oxidative Stress, Inflammation and Cell Death
Khanna, P., Ong, C., Bay, B., & Baeg, G. (2015) · Nanomaterials · doi:10.3390/nano5031163 · Cited by 580
Oyewumi, M. O., Kumar, A., & Cui, Z. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.89 · Cited by 547
Nanoparticle Vaccines Against Infectious Diseases
Pati, R., Shevtsov, M., & Sonawane, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02224 · Cited by 514
Aguilar, J. C., & Rodríguez, E. G. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.111 · Cited by 494
Nanoparticle-Based Immunotherapy for Cancer
Shao, K., Singha, S., Clemente-Casares, X., Tsai, S., Yang, Y., & Santamaria, P. (2015) · ACS Nano · doi:10.1021/nn5062029 · Cited by 470
Core–shell-type lipid–polymer hybrid nanoparticles as a drug delivery platform
Mandal, B., Bhattacharjee, H., Mittal, N., Sah, H., Balabathula, P., Thoma, L. A., & Wood, G. C. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2012.11.010 · Cited by 467
Shen, H., Ackerman, A. L., Cody, V., Giodini, A., Hinson, E. R., Cresswell, P., Edelson, R. L., Saltzman, W. M., & Hanlon, D. J. (2006) · Immunology · doi:10.1111/j.1365-2567.2005.02268.x · Cited by 420
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment
Gu, L., & Mooney, D. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.3 · Cited by 407
Cytokines as biomarkers of nanoparticle immunotoxicity
Elsabahy, M., & Wooley, K. L. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60064e · Cited by 407
Control of polymeric nanoparticle size to improve therapeutic delivery
Hickey, J. W., Santos, J. L., Williford, J.-M., & Mao, H.-Q. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.006 · Cited by 379
Beyond antigens and adjuvants: formulating future vaccines
Moyer, T. J., Zmolek, A. C., & Irvine, D. J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81083 · Cited by 374
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
The coming of age of virus-like particle vaccines
Jennings, G. T., & Bachmann, M. F. (2008) · bchm · doi:10.1515/bc.2008.064 · Cited by 369
Evaluation of nanoparticle immunotoxicity
Dobrovolskaia, M. A., Germolec, D. R., & Weaver, J. L. (2009) · Nature Nanotechnology · doi:10.1038/nnano.2009.175 · Cited by 368
Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer
Kawasaki, E. S., & Player, A. (2005) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2005.03.002 · Cited by 368
Impact of lipid nanoparticle size on mRNA vaccine immunogenicity
Hassett, K. J., Higgins, J., Woods, A., Levy, B., Xia, Y., Hsiao, C. J., Acosta, E., Almarsson, Ö., Moore, M. J., & Brito, L. A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.021 · Cited by 367
Modulation of Immune Responses by Particle Size and Shape
Baranov, M. V., Kumar, M., Sacanna, S., Thutupalli, S., & van den Bogaart, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.607945 · Cited by 324
Virus-like particles: flexible platforms for vaccine development
Chackerian, B. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.3.381 · Cited by 321
Classification and Characterization of Therapeutic Antibody Aggregates
Joubert, M. K., Luo, Q., Nashed-Samuel, Y., Wypych, J., & Narhi, L. O. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.160457 · Cited by 316
Current understanding of interactions between nanoparticles and the immune system
Dobrovolskaia, M. A., Shurin, M., & Shvedova, A. A. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.12.022 · Cited by 309
Mottram, P. L., Leong, D., Crimeen-Irwin, B., Gloster, S., Xiang, S. D., Meanger, J., Ghildyal, R., Vardaxis, N., & Plebanski, M. (2007) · Molecular Pharmaceutics · doi:10.1021/mp060096p · Cited by 296
Self-citationNanomaterials for cancer immunotherapy
Song, W., Musetti, S. N., & Huang, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.017 · Cited by 281
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy
Fan, Y., & Moon, J. (2015) · Vaccines · doi:10.3390/vaccines3030662 · Cited by 275
Joubert, M. K., Hokom, M., Eakin, C., Zhou, L., Deshpande, M., Baker, M. P., Goletz, T. J., Kerwin, B. A., Chirmule, N., Narhi, L. O., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.330902 · Cited by 268
Immunogenicity of protein aggregates—Concerns and realities
Wang, W., Singh, S. K., Li, N., Toler, M. R., King, K. R., & Nema, S. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.04.040 · Cited by 266
Black, M., Trent, A., Tirrell, M., & Olive, C. (2010) · Expert Review of Vaccines · doi:10.1586/erv.09.160 · Cited by 203
Nanoparticle impact on innate immune cell pattern-recognition receptors and inflammasomes activation
Silva, A. L., Peres, C., Conniot, J., Matos, A. I., Moura, L., Carreira, B., Sainz, V., Scomparin, A., Satchi-Fainaro, R., Préat, V., et al. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.003 · Cited by 95
Thomas, C., Gupta, V., & Ahsan, F. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.06.006 · Cited by 79
Metadata
- Authors
- Fifis, T., Gamvrellis, A., Crimeen-Irwin, B., Pietersz, G. A., Li, J., Mottram, P. L., McKenzie, I. F. C., & Plebanski, M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-09-01
- Volume
- 173
- Issue
- 5
- Pages
- 3148-3154
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1567772800
- Cited by
- 664
- References
- 20
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.